Sugi Predict

Sugi Predict / Compounds / SCHEMBL1468486

SCHEMBL1468486

SCHEMBL1468486

COC(=O)c1ccc(F)nc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 3/20 0.65
▸ KDM4E B2RXH2 2/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ ALDH1A1 P00352 3/20 0.50
▸ CA1 P00915 3/20 0.48
▸ CA2 P00918 3/20 0.48
▸ CA12 O43570 2/20 0.48
▸ CA7 P43166 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ CA14 Q9ULX7 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ MAPT P10636 4/20 0.47
▸ RAB9A P51151 4/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ TSHR P16473 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ XDH P47989 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30737466 1.00 MAPK1 (0.65) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL9944384 0.80 CA12 (0.53) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL6087503 0.80 CA12 (0.53) KDM4EL3MBTL1ALDH1A1CA1CA2
SCHEMBL30812042 0.80 CA12 (0.43) MAPK1KDM4EL3MBTL1CA1CA2
SCHEMBL646488 0.80 CA12 (0.43) MAPK1KDM4EL3MBTL1CA1CA2
SCHEMBL29651058 0.80 MAPK1 (0.69) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL29651074 0.80 MAPK1 (0.69) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL70712 0.80 MAPK1 (0.69) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL64688 0.78 MAPK1 (0.67) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL69747 0.78 MAPK1 (1.00) MAPK1KDM4EL3MBTL1ALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637468-B2 Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators Shanghai Simr Biotechnology Co., Ltd. (CN) 2026-05-26 — — US disclosed
US-12630509-B2 Heterocyclic NMDA antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-05-19 — — US disclosed
WO-2026087909-A1 COMPOUNDS FOR USE AS NEUROPROTECTIVE AGENTS AND/OR IN INHIBITING FORMATION OF ALPHA-SYNUCLEIN AGGREGATES AC IMMUNE SA (CH) 2026-04-30 — — WO disclosed
EP-4720060-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2026-04-08 — — EP disclosed
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 — — EP disclosed
EP-4713093-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH ALPHA-SYNUCLEIN AGGREGATES AC Immune SA (CH) 2026-03-25 — — EP disclosed
US-12509439-B2 Anti-malarial agents UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2025-12-30 — — US disclosed
EP-4665331-A1 ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2025-12-24 — — EP disclosed
EP-3837252-B1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-12-10 — — EP disclosed
US-20250345446-A1 BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES DRAUPNIR BIO APS (DK) 2025-11-13 — — US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 — — US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 — — US disclosed
WO-2009097567-A1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2009-08-06 — — WO disclosed
WO-2009097567-A1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2009-08-06 — — WO disclosed
EP-1896395-A2 MODIFIED MALONATE DERIVATIVES Merck & Co., Inc. (US) 2008-03-12 — — EP disclosed
WO-2007135350-A1 BENZOTRIAZEPINONE DERIVATIVES JAMES BLACK FOUNDATION (GB) 2007-11-29 — — WO disclosed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 — — WO disclosed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 — — WO disclosed
WO-1989000560-A1 DIRECT FLUORINATION OF SUBSTITUTED PYRIDINES ALLIED SIGNAL INC (US) 1989-01-26 — — WO disclosed
US-4786733-A CONTACTING WITH FLUORINE GAS ALLIED-SIGNAL INC. (US) 1988-11-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630509-B2 Heterocyclic NMDA antagonists GRIN1, GRIN3A, GRIN2B MAPK1 555/4885KDM4E 575/4885L3MBTL1 3347/4885
US-20100160327-A1 Modified Malonate Derivatives ME2, ME3, ME1 MAPK1 275/4885KDM4E 129/4885L3MBTL1 797/4885
US-12509439-B2 Anti-malarial agents RCC1, PFN1, NHERF1 MAPK1 1211/4885KDM4E 3704/4885L3MBTL1 3793/4885
US-20250345446-A1 BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES SORT1, SCARB1, LAMP1 MAPK1 3611/4885KDM4E 4709/4885L3MBTL1 1760/4885
US-12637468-B2 Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators GABRA6, GABRA1, GABRB1 MAPK1 2422/4885KDM4E 3564/4885L3MBTL1 4704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.